TIGIT and type 1 diabetes mellitus: Our data are in line with a recent report documenting in type 1 diabetic (T1D) patients treated with humanized CD3 monoclonal Ab (teplizumab), the presence of dysfunctional CD8+ T cells qualified as “exhausted-like” and expressing the transcription factor Eomes, TIGIT, and KLRG-1 (28).